Abcellera Biologics Inc Cash Flow Quality Index
Abcellera Biologics Inc cash flow quality index. Abcellera Biologics Inc (ABCL) has a Cash Flow Quality Index of -4.76x as of September 2022. Operating cash flow of $-126.79 Million is below net income of $26.62 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore ABCL cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Abcellera Biologics Inc (2018–2022)
Cash flow quality index of Abcellera Biologics Inc from 2018 to 2022. Historical Cash Flow Quality Index for Abcellera Biologics Inc across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. See ABCL net asset quality index to measure how much of total assets are equity-financed.
Abcellera Biologics Inc Cash Flow Quality Index by Year (2018–2022)
Abcellera Biologics Inc cash flow quality index by year from 2018 to 2022. Year-by-year earnings quality comparison for Abcellera Biologics Inc. For the full cash flow conversion analysis, see cash efficiency ratio of Abcellera Biologics Inc.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2022 | 1.75x | $277.36 Million | $158.52 Million | ▲ +9.8% |
| 2021 | 1.59x | $244.58 Million | $153.46 Million | ▲ +735.3% |
| 2020 | 0.19x | $22.69 Million | $118.92 Million | ▼ -98.3% |
| 2018 | 11.54x | $3.56 Million | $309.00K | — |